Roche puts future investments in Germany on hold over cost cuts

what happened

Swiss drugmaker Roche is reviewing all future investments in Germany because of healthcare cost-cutting measures. Daniel Steiners, head of Roche Germany, said this in an interview with the newspaper Welt, published on Monday.

Steiners said new investment decisions in the country are temporarily frozen and that policymakers have "recently destroyed a lot of trust" in the pharmaceutical industry. He argued that instead of fixing structural problems in the statutory health insurance system, authorities are chasing short-term savings and shifting extra burdens onto drugmakers.

Germany's Health Ministry called the company decisions regrettable and said it would push for stable conditions for the pharma sector, including at EU level. The government said it is reviewing proposals for a location clause, but the outcome cannot yet be predicted. Roche told Reuters that planned investments, such as the expansion of its Penzberg site worth more than 600 million euros, are not affected by the review.

why it matters

Roche's move follows Eli Lilly's June decision to halve its planned German investments of 2.3 billion euros, suggesting that pressure on the drug sector could slow capital inflows. For investors, it flags risks to German healthcare spending and drugmakers, and the fate of the location clause will matter in coming months. The article cites the exchange rate of $1 = 0.8934 euros.

market impact

Фармсектор и немецкие активы: риск сокращения инвестиций из-за новых расходных ограничений

tags

instruments